Fredag 9 Maj | 14:00:14 Europe / Stockholm

Svenska | English

Gubra

Filter

År

Typ

Språk

Rensa

2025-05-09 07:30:00 Trading statement Q1-2025: A landmark deal for GUBamy

2025-04-03 16:17:00 Gubra Welcomes New Board Members at 2025 AGM 416,00 DKK | -2,80% | 39,1 MDKK

2025-04-03 14:06:00 Course of Gubra A/S' Annual General Meeting 2025 416,00 DKK | -2,80% | 39,1 MDKK

2025-04-01 16:52:00 Successful Transaction Closure of License Agreement 448,00 DKK | +8,21% | 74,0 MDKK

2025-04-01 08:45:00 Gubra announces positive GUBamy Phase 1 interim MAD results 448,00 DKK | +8,21% | 74,0 MDKK

2025-03-28 22:32:00 Regulatory Condition Satisfied for License Agreement between AbbVie and Gubra

2025-03-10 12:57:00 NOTICE TO CONVENE ANNUAL GENERAL MEETING 2025 465,00 DKK | -9,18% | 55,5 MDKK

2025-03-03 07:08:00 AbbVie and Gubra Announce License Agreement to Develop an Amylin Analog for the Treatment of Obesity 650,00 DKK | +15,25% | 198 MDKK

2025-02-28 07:30:00 Annual Report 2024: Excellent performance across Gubra 564,00 DKK | -12,42% | 187 MDKK

2025-01-15 07:30:00 Gubra appoints new Chief Operating Officer 670,00 DKK | +0,90% | 7,93 MDKK

2024-12-30 13:30:00 Gubra Announces New Collaboration with Amylyx Pharmaceuticals to Develop a Novel Long-acting GLP-1 Receptor Antagonist 624,00 DKK | -0,95% | 29,4 MDKK

2024-11-13 18:36:00 Gubra announces positive GUBamy Phase 1 SAD data (correction) 686,00 DKK | +43,51% | 224 MDKK

2024-11-13 17:41:00 Gubra announces positive GUBamy Phase 1 SAD data 686,00 DKK | +43,51% | 224 MDKK

2024-11-07 07:30:00 Trading statement Q3-2024: Another strong quarter 425,00 DKK | -1,39% | 19,6 MDKK

2024-10-31 11:07:00 Gubra announces discontinuation of development of NYP2 in obesity with Boehringer Ingelheim 430,00 DKK | -4,02% | 69,2 MDKK

2024-09-06 21:42:00 Major shareholder announcement

2024-08-22 07:30:00 Interim report H1 2024: Strong performance across Gubra 620,00 DKK | +1,31% | 78,0 MDKK

2024-08-21 17:12:00 Gubra raises financial outlook for 2024 620,00 DKK | +1,31% | 78,0 MDKK

2024-07-10 23:38:00 Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares 628,00 DKK | +14,18% | 140 MDKK

2024-07-02 20:25:00 Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares 590,00 DKK | +4,24% | 52,7 MDKK

2024-07-01 07:30:00 Boehringer Ingelheim and Gubra announce start of clinical development of a potential first-in-class, triple agonist, obesity treatment 602,00 DKK | +23,11% | 119 MDKK

2024-06-28 12:05:00 Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares 489,00 DKK | +6,30% | 35,7 MDKK

2024-06-04 15:30:00 Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares 326,00 DKK | -0,61% | 6,72 MDKK

2024-06-04 15:25:00 Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares 326,00 DKK | -0,61% | 6,72 MDKK

2024-05-07 07:30:00 Trading statement Q1-2024: Strong start to the year 348,00 DKK | +12,62% | 66,8 MDKK

2024-05-06 17:15:00 Gubra raises financial outlook for 2024 348,00 DKK | +12,62% | 66,8 MDKK

2024-04-17 07:30:00 Gubra unveils UCN2 as novel anti-obesity drug candidate for healthy weight loss 304,00 DKK | +8,96% | 25,7 MDKK

2024-04-04 12:32:00 RESOLUTIONS OF GUBRA A/S' ANNUAL GENERAL MEETING 2024 299,00 DKK | +0,67% | 12,9 MDKK

2024-04-03 21:45:00 Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares 299,00 DKK | +0,67% | 12,9 MDKK

2024-04-03 21:35:00 Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares 299,00 DKK | +0,67% | 12,9 MDKK

2024-03-27 14:45:00 Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares 291,00 DKK | +11,92% | 35,8 MDKK

2024-03-26 22:45:00 Major shareholder announcement: The Capital Group Companies Inc. 291,00 DKK | +11,92% | 35,8 MDKK

2024-03-25 11:29:00 Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares 281,00 DKK | -6,33% | 182 MDKK

2024-03-25 09:56:00 Major shareholder announcement 281,00 DKK | -6,33% | 182 MDKK

2024-03-06 09:00:00 NOTICE TO CONVENE ANNUAL GENERAL MEETING 2024 221,00 DKK | +0,45% | 12,1 MDKK

2024-03-04 21:41:00 Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares 220,00 DKK | +4,76% | 22,6 MDKK

2024-02-28 07:30:00 Annual Report 2023 – Revenue in the CRO business growing by 29% to record high level 185,00 DKK | +8,82% | 7,37 MDKK

2024-01-26 13:33:00 Gubra concludes the research agreement with UK Biotech 121,00 DKK | -0,82% | 0,10 MDKK

2023-12-13 17:19:00 Gubra and Boehringer Ingelheim sign 4th partnership, expanding their successful obesity treatment discovery collaboration 124,00 DKK | +4,84% | 7,09 MDKK

2023-11-29 12:51:00 Gubra announces first subject dosed in Phase 1 clinical trial of amylin agonist (GUBamy) for the treatment of obesity 117,04 DKK | +2,11% | 0,01 MDKK

2023-11-08 07:30:00 Trading statement Q3-2023: Continued strong performance 113,00 DKK | -0,62% | 0,46 MDKK

2023-11-01 11:01:00 Gubra strengthens Board of Directors 109,98 DKK | -0,02% | 0,07 MDKK

2023-11-01 10:40:00 Gubra - Extraordinary general meeting 109,98 DKK | -0,02% | 0,07 MDKK

2023-10-26 12:35:00 Gubra enters into a Market Maker Agreement 100,98 DKK | +7,19% | 0,24 MDKK

2023-10-26 08:01:00 Gubra raises financial guidance for full-year 2023 100,98 DKK | +7,19% | 0,24 MDKK

2023-10-24 07:30:00 Gubra opens its first US office in Boston 94,20 DKK | -0,89% | 0,04 MDKK

2023-10-09 14:00:00 NOTICE TO CONVENE EXTRAORDINARY GENERAL MEETING 104,02 DKK | -0,04% | 0,01 MDKK

2023-09-06 09:58:00 Gubra submits clinical trial application (CTA) for first-in-human amylin trial 116,60 DKK | +4,82% | 1,06 MDKK

Visa fler

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Gubra

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden